Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data.

A meta-analysis of 8 randomized trials (1792 patients, 2947 patient-years of follow-up) showed that acyclovir (> or = 3200 mg/day) offered a significant survival benefit (P = .006 by log-rank test) in human immunodeficiency virus (HIV) infection. The treatment effect did not vary significantly in patient subgroups of different CD4 cell counts, hemoglobin levels, age, race, and sex, and with or without AIDS diagnosis. Acyclovir treatment (hazard ratio, 0.78; 95% confidence interval [CI], 0.65-0.93), higher CD4 cell count (P < .001), higher hemoglobin level (P < .001), and younger age (P < .001) reduced the hazard of mortality. Acyclovir decreased herpes simplex virus infections (odds ratio [OR], 0.28; 95% CI, 0.21-0.37) and varicella-zoster virus infections (OR, 0.29; 95% CI, 0.13-0.63) but not cytomegalovirus disease or mortality from lymphoma or Kaposi's sarcoma. A survival advantage was seen specifically in studies with high incidence of clinical herpesvirus infections (> or = 25% per year). Given the wide confidence intervals, the small effect in low-risk patients, and recent changes in HIV therapeutics, the results should be interpreted cautiously, but the meta-analysis supports the importance of pathogenetic interactions between herpesviruses and HIV.

[1]  D. Carnall.  Randomised controlled trials , 1999, BMJ.

[2]  J. Ioannidis.  Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.

[3]  Christopher H Schmid,et al.  Summing up evidence: one answer is not always enough , 1998, The Lancet.

[4]  S. Yusuf,et al.  Overcoming the limitations of current meta-analysis of randomised controlled trials , 1998, The Lancet.

[5]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[6]  D. Cooper,et al.  A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection , 1998 .

[7]  J. Zeh,et al.  Famciclovir for the Suppression of Symptomatic and Asymptomatic Herpes Simplex Virus Reactivation in HIV-Infected Persons: A Double-Blind, Placebo-Controlled Trial , 1998, Annals of Internal Medicine.

[8]  C. Sabin,et al.  The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. , 1998, The Journal of infectious diseases.

[9]  D. Nelson,et al.  Pathogenesis of chronic hepatitis C virus infection. , 1998, Antiviral therapy.

[10]  J. Cherrington,et al.  The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. , 1997, The Journal of infectious diseases.

[11]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[12]  J. Lau,et al.  The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.

[13]  L. Mole,et al.  The impact of active herpes simplex virus infection on human immunodeficiency virus load. , 1997, The Journal of infectious diseases.

[14]  D. Ganem,et al.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. , 1997, The Journal of clinical investigation.

[15]  R. Chaisson,et al.  Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. , 1997, Antiviral therapy.

[16]  J. Ioannidis,et al.  Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. An example from patient populations in trials of human immunodeficiency virus infection. , 1996, American journal of epidemiology.

[17]  N. Graham,et al.  Interaction of Herpes Viruses with HIV: Can Antiherpes Drugs Prolong Survival Among AIDS Patients? , 1996, Reviews in medical virology.

[18]  B. Gazzard,et al.  Anti‐herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection , 1996, AIDS.

[19]  J. Phair,et al.  Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. , 1996, The Journal of infectious diseases.

[20]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[21]  M. Wachsman,et al.  Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. , 1996, Antiviral research.

[22]  J. Ioannidis,et al.  Predictive value of viral load measurements in asymptomatic untreated HIV‐1 infection: a mathematical model , 1996, AIDS.

[23]  A. Collier,et al.  Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients , 1995, Antimicrobial agents and chemotherapy.

[24]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[25]  M. Pope,et al.  Enhanced HIV-1 replication in Vβ12 T cells due to human cytomegalovirus in monocytes: Evidence for a putative herpesvirus superantigen , 1995, Cell.

[26]  Richard D Moore,et al.  Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine , 1995 .

[27]  H. Sacks,et al.  Early or Deferred Zidovudine Therapy in HIV-Infected Patients without an AIDS-Defining Illness , 1995, Annals of Internal Medicine.

[28]  J. Phair,et al.  The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival: Analysis of Data in the Multicenter AIDS Cohort Study , 1994, Annals of Internal Medicine.

[29]  B. Gazzard,et al.  Effects of high‐dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double‐blind, placebo‐controlled study , 1994 .

[30]  S. Allen,et al.  Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1 , 1994, The Lancet.

[31]  I. Weller,et al.  Epstein‐Barr virus infection of HIV‐seropositive individuals is transiently suppressed by high‐dose acyclovir treatment , 1993, AIDS.

[32]  M. Moroni,et al.  The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS‐related complex: a double‐blind, randomized trial , 1993 .

[33]  P. Griffiths.  Studies to define viral cofactors for human immunodeficiency virus. , 1992, Infectious agents and disease.

[34]  S. Hammer,et al.  Activation of human immunodeficiency virus by herpes simplex virus. , 1992, The Journal of infectious diseases.

[35]  Ruedi Lüthy,et al.  The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS‐related complex , 1992, AIDS.

[36]  F. Lori,et al.  Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6 , 1991, Nature.

[37]  J. Pagano,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Replication by Guanosine Analogues and Lack of Synergistic Antiviral Effect of Acyclovir with 3′-azido-3′-deoxythymidine , 1991 .

[38]  D. Richman,et al.  A pilot study of low-dose zidovudine in human immunodeficiency virus infection. , 1990, The New England journal of medicine.

[39]  J. Laurence,et al.  Molecular interactions among herpesviruses and human immunodeficiency viruses. , 1990, The Journal of infectious diseases.

[40]  J. Goudsmit,et al.  Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects. , 1990, Antiviral research.

[41]  S. Aho,et al.  A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients. , 1990, Cancer detection and prevention.

[42]  H. Mitsuya,et al.  Strategies for antiviral therapy in AIDS , 1987, Nature.

[43]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[44]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .